Lung Transplantation in Sarcoidosis

Lung transplantation may be considered for a small number of people with advanced, irreversible lung disease and severe respiratory impairment despite optimal treatment.

Assessment includes lung function, heart function, other organs, nutrition, infection risk and ability to follow long-term treatment. Transplantation requires lifelong immunosuppression and specialist follow-up.

Autoimmune conditions not linked to worse lung transplant outcomes

Author: Patricia Inácio, PhD

People with autoimmune diseases such as sarcoidosis are not at greater risk of worse outcomes after lung or heart-lung transplantation compared with people without such diseases, according to a single-centre study.

The findings that patients with autoimmune diseases do as well as others after these transplants challenge the long-standing standard approach of denying them lung transplantation because of concerns about complications after transplantation.

“All patients with an autoimmune disease causing severe lung damage who would consider lung transplantation should be referred to a transplant centre for evaluation,” Jason H. Melehani, MD, PhD, a co-author of the study, said in a press release.

Melehani, a rheumatology and pulmonary medicine fellow at Stanford Medical Center, presented the results at the virtual ACR Convergence, the annual meeting of the American College of Rheumatology, in a poster entitled “Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study”.

Systemic autoimmune diseases are a common cause of irreversible lung damage, contributing to severe lung disease and early mortality. In most cases, lung transplantation is the only option for these patients, but many transplant centres exclude them from surgery because of concerns about their outcomes after transplantation.

In particular, doctors were concerned that these patients’ overactive immune systems could cause complications after transplantation and damage outside the lungs.

“As a result of their systemic disease and previous immunosuppressive treatments, patients with autoimmune diseases present unique challenges when undergoing lung transplantation. Studying and addressing these challenges is essential to being able to offer this life-saving intervention to the many patients who need it,” Melehani said.

To clarify whether outcomes after lung transplantation in patients with autoimmune diseases differed so much from those of people without such conditions, researchers at Stanford University in Palo Alto, California, conducted a retrospective analysis of patients who received lung or heart-lung transplants at the centre from 2005 to 2019.

During that period, a total of 75 transplant recipients had systemic autoimmune disorders, including 17 with rheumatoid arthritis, 16 with scleroderma, 15 with sarcoidosis, 14 with idiopathic inflammatory myositis, eight with Sjögren’s syndrome, four with mixed connective tissue disease and one with systemic lupus erythematosus.

As controls, the researchers included a group of 152 patients without autoimmune diseases who also underwent transplantation during the same period. Two controls were matched to each patient by age, sex, year of transplantation, reason for transplantation (such as interstitial lung disease versus pulmonary hypertension), and type of procedure (single-lung, double-lung or heart-lung).

The study aimed to determine the survival rates of people with and without autoimmune diseases after their transplant. The results showed that 79.4% of those with autoimmune diseases and 90.3% of the control group were alive one year after transplantation, and that 54.9% and 57.7% in the respective groups lived for at least five years after transplantation.

Although further analysis showed a trend towards better survival in the group without autoimmune diseases, the findings did not reach statistical significance, indicating no significant differences in survival between the groups.

Overall, these findings show that patients with autoimmune diseases and severe lung disease are not at greater risk of worse outcomes after lung or heart-lung transplantation.

“These data, together with previous reports from other centres, position lung transplantation as an important treatment option even for patients with systemic autoimmune diseases. This study will serve as a starting point for our efforts to improve treatment and outcomes for this patient population,” Melehani said.

Source: https://sarcoidosisnews.com/news/autoimmune-conditions-not-linked-worse-lung-transplant-outcomes/

Rating: 0 stars, 0 votes.